Actinium Pharmaceuticals, Inc. (ATNM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 30, 2023, covers the results of Actinium Pharmaceuticals, Inc.'s 2023 Annual Meeting of Stockholders. The filing details the election of directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and voting results rather than financial performance.
Material Changes and Voting Results
A total of 16,495,465 shares were present or represented by proxy at the Annual Meeting. The following proposals were voted upon:
- Election of Class I Directors:
- David Nicholson: Elected with 3,959,659 votes "For," 3,275,844 "Withheld," and 9,087,835 Broker Non-Votes.
- Richard I. Steinhart: Elected with 5,630,379 votes "For," 1,777,251 "Withheld," and 9,087,835 Broker Non-Votes.
- Both directors were elected to serve for a three-year term expiring at the 2026 Annual Meeting.
- Ratification of Independent Auditor:
- Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes: 15,842,146 "For," 372,774 "Against," and 280,545 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to report the final voting results of the Annual Meeting.
Key Facts for Investor Verification
- David Nicholson received a significant number of "Withheld" votes (3,275,844) compared to "For" votes (3,959,659), indicating notable shareholder dissent despite his election.
- Broker Non-Votes were substantial (9,087,835) for both director elections, representing a large portion of the shares present.
- Marcum LLP was overwhelmingly ratified as the independent auditor.
- The filing confirms the terms of the newly elected Class I directors expire at the 2026 Annual Meeting.